Literature DB >> 20960378

Novel insights into the pathophysiology of nonalcoholic fatty liver disease.

Ariel E Feldstein1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver disease affecting both adults and children in the United States and many other parts of the world. NAFLD encompasses a wide spectrum of conditions associated with overaccumulation of lipids in the liver. It is strongly associated with obesity and insulin resistance and has been growingly recognized as an independent risk factor for cardiovascular disease. In this review, recently uncovered novel aspects of the molecular events responsible for the development and progression of this highly prevalent and potentially serious disease are discussed. These studies bring new insights that may significantly impact the clinical approach to patients with NAFLD, from novel diagnostics to innovative therapeutic strategies. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960378     DOI: 10.1055/s-0030-1267539

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  49 in total

1.  Two polymorphisms of USF1 gene (-202G>A and -844C>T) may be associated with hepatocellular carcinoma susceptibility based on a case-control study in Chinese Han population.

Authors:  Xu Zhou; Hua-qiang Zhu; Chao-qun Ma; Hong-guang Li; Fang-feng Liu; Hong Chang; Jun Lu
Journal:  Med Oncol       Date:  2014-11-01       Impact factor: 3.064

Review 2.  Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Alexander Wree; Wajahat Z Mehal; Ariel E Feldstein
Journal:  Semin Liver Dis       Date:  2016-02-12       Impact factor: 6.115

Review 3.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.

Authors:  Jamie E Mells; Ping P Fu; Shvetank Sharma; Darin Olson; Lihong Cheng; Jeffrey A Handy; Neeraj K Saxena; Dan Sorescu; Frank A Anania
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-28       Impact factor: 4.052

Review 5.  Human fatty liver disease: old questions and new insights.

Authors:  Jonathan C Cohen; Jay D Horton; Helen H Hobbs
Journal:  Science       Date:  2011-06-24       Impact factor: 47.728

6.  Mechanism of the promotion of steatotic HepG2 cell apoptosis by cholesterol.

Authors:  Chunyan Zhu; Ping Xie; Fei Zhao; Lingqiang Zhang; Wei An; Yutao Zhan
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

7.  Adipose tissue-liver crosstalk during pathologic changes caused by vinyl chloride metabolites in mice.

Authors:  Brenna R Kaelin; Collin M McKenzie; Karl W Hempel; Anna L Lang; Gavin E Arteel; Juliane I Beier
Journal:  Toxicol Appl Pharmacol       Date:  2020-05-20       Impact factor: 4.219

Review 8.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 9.  Innate immune activation in obesity.

Authors:  Carey N Lumeng
Journal:  Mol Aspects Med       Date:  2012-10-13

10.  Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis.

Authors:  Lars P Bechmann; Diana Vetter; Junichi Ishida; Rebekka A Hannivoort; Ursula E Lang; Peri Kocabayoglu; M Isabel Fiel; Ursula Muñoz; Gillian L Patman; Fengxia Ge; Shoshana Yakar; Xiaosong Li; Loranne Agius; Young-Min Lee; Weijia Zhang; Kei Yiu Hui; Despina Televantou; Gary J Schwartz; Derek LeRoith; Paul D Berk; Ryozo Nagai; Toru Suzuki; Helen L Reeves; Scott L Friedman
Journal:  J Hepatol       Date:  2013-01-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.